NCT00674323View on ClinicalTrials.gov

Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy

PHASE4CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

May 31, 2009

Conditions
Polypoidal Choroidal Vasculopathy
Interventions
DRUG

Verteporfin Photodynamic Therapy

After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, light application of 50 J/cm\^2 to the study eye was begun 15 minutes after the start of infusion.

DRUG

Ranibizumab

Ranibizumab at dose of 0.5 mg administered as an intravitreal injection.

Trial Locations (5)

Unknown

Novartis Investigative Site, Hong Kong

Novartis Investigative Site, Singapore

Novartis Investigative Site, Seoul

Novartis Investigative Site, Taipei

Novartis Investigative Site, Bangkok

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY